<DOC>
	<DOC>NCT01942369</DOC>
	<brief_summary>The purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline (Triptorelin Acetate) treatment for up to 24 weeks.</brief_summary>
	<brief_title>A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Patients diagnosed with DIE and having received surgery treatment within one month before inclusion Premenopausal women aged &gt;=18 years old. Patient for whom the treating physician already made the decision to treat by Diphereline. Patient should be mentally and physically able to express her symptom complaints and answer questions. Pregnancy or lactation. Patients currently on treatment or who have been on therapy with a GnRHa in the last 6 months. Premenopausal women who may reach menopause within the 3 years post randomisation. Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg Treatment with another research drug over the last 3 months before the study Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Endometriosis</keyword>
</DOC>